Genmab chief on sclerosis drug launch: Novartis prioritizes us
![Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12869468.ece/ALTERNATES/schema-16_9/doc7f4wileremf1c03mijjv.jpg)
On Tuesday, the EU Commission approved the drug Kesimpta, which was developed by Genmab, as a treatment for sclerosis.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.